Stents combined with paclitaxel derivatives

Abstract

Stents are used in combination with a paclitaxel derivative in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. Suitable implants include vascular stents, esophageal stents, tracheal or bronchial stents, gastrointestinal stents, genital-urinary stents, nasal and sinus stents, and ENT stents.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60 / 653,844, filed Feb. 17, 2005, which application is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates generally to pharmaceutical compositions that include paclitaxel derivatives and methods for preparing and using stent devices to make them resistant to overgrowth by inflammatory and fibrous scar tissue.[0004]2. Description of the Related Art[0005]The clinical function of numerous medical implants and devices is dependent upon the device being able to effectively maintain an anatomical, or surgically created, space or passageway. Unfortunately, many devices implanted in the body are subject to a “foreign body” response from the surrounding host tissues. In particular, injury to tubular anatomical structures (such as blood vessels, the gastroin...

AI Technical Summary

Benefits of technology

[0009]In one aspect, the present invention provide a device, comprising a stent and a paclitaxel derivative or a composition comprising a paclitaxel derivative, wherein the paclitaxel derivative inhibits scarring between the device and a host into which the device is implanted.

[0030]In one aspect, the present invention provides methods for inhibiting fibrosis comprising placing a medical device that is coated or otherwise contains a paclitaxel derivative or a composition comprising a paclitaxel derivative. Paclitaxel derivatives and compositions comprising paclitaxel derivatives contained in medical devices reduce the foreign body response to implantation of the medical devices and limit the growth of reactive tissue on the surface of, or around in the tissue surrounding the devices, such that performance is enhanced. In many instances, the devices are used to maintain body lumens or passageways such as blood vessels, the gastrointestinal tract, the male and female reproductive tract, the urinary tract, bony foramena (e.g., sinuses, spinal nerve root canals, lacrimal ducts, Eustachian tubes, the auditory canal), and the respiratory tract, where obstruction of the device by scar tissue in the post-procedural period leads to the adverse clinical sequela or failure of the intervention. Medical devices coated with, or otherwise containing, paclitaxel derivatives designed to prevent scar tissue overgrowth and preserve patency can offer significant clinical advantages over uncoated devices.

Problems solved by technology

Unfortunately, many devices implanted in the body are subject to a “foreign body” response from the surrounding host tissues.

In particular, injury to tubular anatomical structures (such as blood vessels, the gastrointestinal tract, the male and female reproductive tract, the urinary tract, sinuses, spinal nerve root canals, lacrimal ducts, Eustachian tubes, the auditory canal, and the respiratory tract) from surgery and / or injury created by the implantation of medical devices can lead to a well known clinical problem called “stenosis” (or narrowing).

Stenosis occurs in response to trauma to the epithelial lining or the entire body tube during the procedure, including virtually any manipulation which attempts to relieve obstruction of the passageway, and is a major factor limiting the effectiveness of invasive treatments for a variety of diseases to be described later.

Physical injury during an interventional procedure results in damage to epithelial lining of the tube and the smooth muscle cells (SMCs) that make up the wall.

Images